Stage 3 vulvar cancer is curable in a meaningful fraction of cases, though the odds are tougher than for earlier-stage disease. Large registry data from Germany put the five-year survival rate for stage III at roughly 52%, meaning about half of patients are alive five years after diagnosis.1PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study That number, while sobering, also means a cure is achievable for many patients, and the specifics of each case matter enormously in determining where someone lands on the spectrum.
What Stage 3 Actually Means
Vulvar cancer staging was overhauled in 2021 by the International Federation of Gynecology and Obstetrics (FIGO), and the current system divides stage III into three substages. These substages reflect different degrees of local spread and lymph node involvement. The key distinction at stage III is that the cancer has either grown into nearby structures like the lower urethra, vagina, or anus, or it has spread to regional lymph nodes in the groin. The 2021 revision was the first FIGO vulvar cancer staging derived from actual data analyses rather than expert opinion alone, and it incorporates imaging findings alongside surgical and pathological data.2PubMed Central. FIGO staging for carcinoma of the vulva: 2021 revision The survival curves between the three substages show clear separation, so not all stage III disease carries the same prognosis.
This matters because a patient with a single small lymph node metastasis has a very different outlook from someone with multiple enlarged groin nodes or tumor extending into the urethra. When your oncologist says “stage III,” the substage is worth asking about.
The Survival Numbers and What Drives Them
The roughly 52% five-year survival rate for stage III comes from a large German registry study spanning thousands of patients. For context, the same study reported five-year survival of about 84% for stage I, 65% for stage II, and 33% for stage IVA.1PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study An older surgical series reported higher numbers for stage III, with five-year survival around 77%, though that study used different staging criteria and included a more selective patient population.3PubMed. Stage III and IV squamous cell carcinoma of the vulva The difference between these figures reflects changes in staging definitions over time and the fact that registry data captures a broader, more real-world population than surgical series do.
Two factors consistently emerge as the strongest predictors of how well someone does: lymph node status and tumor size. Both were confirmed as independent factors influencing survival in the German registry analysis.1PubMed Central. Influence of stage and age on survival of patients with vulvar cancer in Germany: a retrospective study Older data illustrate this dramatically. In one large series, patients with negative lymph nodes had a corrected five-year survival of 96%. With one positive node, that barely dropped to 94%. With two positive nodes it fell to 80%, and with three or more positive nodes on one side, survival plummeted to 12%.4PubMed. Management of regional lymph nodes and their prognostic influence in vulvar cancer The number of affected lymph nodes is, in many ways, a more meaningful prognostic indicator than the stage label itself.
Older age and stage III disease have both been identified separately as poor prognostic factors in large cohort analyses.5PubMed. Vulvar cancer survival by primary treatment modality: A retrospective cohort study Since vulvar cancer disproportionately affects older women, the intersection of advanced stage and age-related health challenges is a real and common clinical problem.
How Stage 3 Vulvar Cancer Is Treated
Treatment for stage III disease almost always involves some combination of surgery, radiation, and sometimes chemotherapy. The sequencing and extent of each component depends on the specific anatomy of the tumor, which structures are involved, and the patient’s overall fitness.
Surgery and Margins
Radical surgery remains the backbone of treatment when it can achieve clear margins without unacceptable loss of function. How wide those margins need to be has been studied extensively. A meta-analysis of ten studies found that a tumor-free margin of less than 8 millimeters on the pathology specimen was associated with roughly double the risk of local recurrence compared to margins of 8 mm or more.6PubMed. Tumour-free margins in vulvar squamous cell carcinoma: Does distance really matter? An Australian study confirmed this threshold and added that patients with margins under 5 mm who received either re-excision or radiation therapy had a significantly decreased recurrence risk, suggesting that close margins can be managed if caught.7PubMed Central. The Prognostic Role of the Surgical Margins in Squamous Vulvar Cancer: A Retrospective Australian Study The clinical goal is a 1-centimeter surgical margin, which after tissue shrinkage during processing typically yields about 8 mm on the pathology slide.
Lymph node dissection in the groin is a standard part of treatment at this stage. The majority of surgeons worldwide remove both superficial and deep groin lymph nodes, though practice varies by region.8International Journal of Gynecological Cancer. Technique for inguino-femoral lymph node dissection in vulvar cancer: an international survey For patients with positive nodes, adjuvant radiation is generally recommended, especially when two or more nodes are involved or margins are close.9PubMed Central. Adjuvant Radiation in Early Stage Vulvar Cancer: A Review of Indications and Optimal Dose
Neoadjuvant Chemoradiation
When the tumor is large or positioned in a way that would require removing the urethra, anus, or other critical structures, giving chemotherapy and radiation before surgery can shrink the tumor enough to allow a less mutilating operation. This approach has been studied specifically in locally advanced vulvar cancer. In one series, about 45% of patients achieved complete disappearance of tumor in the vulvar specimen after neoadjuvant chemoradiation, and about 27% had no tumor remaining in either the vulvar or lymph node specimens.10PubMed Central. Neoadjuvant chemoradiotherapy followed by surgery in locally advanced squamous cell carcinoma of the vulva
A pooled reanalysis comparing treatment strategies for stage III and IV disease found that neoadjuvant therapy followed by surgery led to a five-year survival of about 73%, compared to 43% for patients treated with chemoradiation alone without subsequent surgery. Patients who responded well to the neoadjuvant treatment had substantially better outcomes than those who did not (67% vs. 20% five-year survival).11PubMed. Neoadjuvant and definitive chemotherapy or chemoradiation for stage III and IV vulvar cancer: A pooled Reanalysis A Cochrane review, however, found no clear survival advantage for neoadjuvant chemoradiation over primary surgery in the randomized trial data available, reflecting the persistent uncertainty in comparing these strategies head-to-head.12PubMed Central. Chemoradiation for advanced primary vulval cancer The upshot is that for many stage III patients, the goal of neoadjuvant treatment is less about improving survival outright and more about making surgery feasible and less disfiguring.
Why the Tumor’s Biology Matters as Much as Its Size
Vulvar squamous cell carcinoma comes in molecularly distinct flavors, and the biology of the tumor turns out to be a significant predictor of how things go. The main split is between cancers driven by HPV infection and those that arise independently of HPV, often carrying mutations in the p53 gene. Patients with HPV-positive tumors have the most favorable outcomes. Those with HPV-negative, p53-mutated tumors fare worst, with roughly three and a half times the risk of death compared to the HPV-positive group.13Gynecologic Oncology. Prognostic significance of molecular classification in vulvar squamous cell carcinoma
A third group exists: tumors that are HPV-negative but have normal (wild-type) p53. A recent meta-analysis placed this group at intermediate risk, with outcomes significantly better than the p53-mutated group but significantly worse than HPV-positive cancers.14PubMed. Prognosis of HPV-independent, p53-wild-type vulvar squamous cell carcinoma: A systematic review and meta-analysis In terms of local recurrence specifically, HPV-positive tumors with wild-type p53 had the lowest rates, while HPV-negative/p53-mutated tumors had the highest.15PubMed Central. Prognostic value of HPV-PCR, p16 and p53 immunohistochemical status on local recurrence rate and survival in patients with vulvar squamous cell carcinoma
This molecular classification is increasingly being used to guide treatment intensity. A patient with an HPV-positive stage III tumor may have a meaningfully better outlook than the stage-wide average suggests, while someone with a p53-mutated tumor may need more aggressive monitoring and possibly consideration for clinical trials. Not all treatment centers test for molecular subtype yet, but it is becoming a more standard part of the workup.
Recurrence Patterns
Even after successful initial treatment, recurrence is a real concern. In a large French multicenter study, about 30% of surgically treated vulvar cancer patients experienced recurrence. The majority of recurrences were local or regional (around 18%), with distant spread alone in only about 3% and multifocal recurrences in roughly 10%. The median time to recurrence was 13 months.16PubMed. Patterns of first recurrence and outcomes in surgically treated women with vulvar cancer: results from FRANCOGYN study group Recurrence patterns and timing varied significantly by FIGO stage, lymph node status, and the presence of lymphovascular space invasion.
The finding that most recurrences are local rather than distant is actually somewhat encouraging. Local recurrences, caught early, can sometimes be treated with further surgery or radiation. An older series of stage III patients specifically found that about 73% of recurrences occurred within the local operated area.3PubMed. Stage III and IV squamous cell carcinoma of the vulva The factors that predict local recurrence include deep stromal invasion, while lymph node extracapsular involvement predicted regional recurrence.17American Journal of Clinical Oncology. Predictors and Patterns of Local, Regional, and Distant Failure in Squamous Cell Carcinoma of the Vulva
When vulvar cancer does recur in the pelvis, treatment options become more difficult. Pelvic exenteration, an extensive surgery that can involve removal of the bladder and rectum, carries high morbidity and profoundly affects quality of life. Some centers are exploring alternatives like electrochemotherapy for perineal recurrences, though this remains investigational.18PubMed Central. Electrochemotherapy as an Alternative Treatment Option to Pelvic Exenteration for Recurrent Vulvar Cancer of the Perineum Region
Treatment Side Effects and Long-Term Quality of Life
The treatment required for stage III disease is extensive, and the side effects reflect that. One of the most common and persistent problems is lower-limb lymphedema after groin lymph node dissection. A meta-analysis found that the incidence of lymphedema was roughly five times higher in patients who had full groin node dissection compared to those who had sentinel node biopsy alone. Risk factors included wound infection, the extent of lymph node surgery, older age, higher body mass, and radiation therapy.19PubMed Central. Incidence of lower limb lymphedema after vulvar cancer A systematic review and meta-analysis Since most stage III patients need full lymph node dissection rather than sentinel biopsy, lymphedema is a frequent reality.
Surgical wound complications are also common. In one prospective study using negative-pressure wound therapy after groin lymph node removal, 55% of patients still developed a surgical site complication, including lymphoceles and wound infections.20PubMed Central. Negative Pressure Wound Therapy (NPWT) in Groin Wounds After Lymphadenectomy in Vulvar Cancer Patients
Beyond immediate surgical recovery, the long-term effects on quality of life are substantial. A longitudinal study found that physical functioning, social functioning, fatigue, pain, and sexual health were all significantly worse at 12 months after treatment than before it began. Women with advanced-stage disease had significantly worse mental health scores compared to those treated for early-stage cancer.21PubMed Central. The impact of surgery for vulval cancer upon health-related quality of life and pelvic floor outcomes during the first year of treatment: a longitudinal, mixed methods study A Norwegian cross-sectional study of long-term survivors found that about 43% reported impaired physical functioning and 30% had impaired emotional, cognitive, or social functioning. Only about 20% of survivors were sexually active, compared to roughly 69% in a normative sample, and those who were sexually active reported higher dysfunction.22PubMed Central. Long-term quality of life, vulvar symptoms, and sexual functioning: A cross-sectional study of Norwegian vulvar cancer survivors
A prospective follow-up study tracking sexuality and body image over two years found that the proportion of women who were sexually active actually increased from about 10% at baseline to 23% at 24 months, suggesting some recovery over time. Still, for more than a quarter of women at two years out, the cancer diagnosis itself remained a reason they were not sexually active.23International Journal of Gynecological Cancer. Prospective long-term follow-up of sexuality and body image in women with primary vulvar cancer The point is that surviving stage III vulvar cancer often means living with ongoing physical and emotional consequences. Reconstruction techniques using tissue flaps can help restore anatomy and function after radical surgery, though these procedures add complexity to an already demanding recovery.24PubMed Central. Secondary Vulvar Reconstruction Using Bilateral Gluteal Fold Flaps after Radical Vulvectomy with Direct Closure
When the Patient Is Older or Frail
Vulvar cancer is predominantly a disease of older women, and many patients have other health issues that complicate treatment. A single-center study found that when a geriatrician was involved in treatment planning, half of frail patients received de-escalated treatment, such as less extensive surgery or modified radiation schedules. The reassuring finding was that de-escalated treatment did not compromise survival in these patients.25PubMed. Frailty and treatment decisions in older patients with vulvar cancer: A single-center cohort study Frailty, cognitive impairment, and functional dependency all factored into decisions to scale back treatment intensity.
For patients who do receive adjuvant radiation, the quality of radiation delivery matters a great deal. A study of elderly patients with node-positive vulvar cancer found that only about half of those who started radiation achieved all three quality benchmarks the researchers measured: completing at least 20 fractions, finishing treatment in under eight weeks, and having less than one week of treatment breaks. Patients who met all three benchmarks had notably better survival than those who did not, with a 38% lower risk of death compared to surgery alone. Patients who started radiation but did not meet the benchmarks saw much smaller and less certain benefit.26PubMed Central. Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer The implication is that radiation that gets interrupted or truncated may not help much, and treatment teams need to plan realistically for what a patient can tolerate.
Diagnostic Delays and How They Affect Stage at Diagnosis
One frustrating aspect of vulvar cancer is how often it gets diagnosed late. A German study examining gynecological practice records found that vulvar inflammation was diagnosed an average of 328 days before the eventual cancer detection. Other vulvar conditions, including atrophy and cysts, preceded cancer diagnosis by about 300 days. These conditions also carried an increased risk of later vulvar cancer, suggesting that some cases may represent missed or delayed recognition of malignancy or its precursors.27PubMed Central. Potential delay in the diagnosis of vulvar cancer and associated risk factors in women treated in German gynecological practices A diagnostic delay averaging nearly a year has obvious implications for what stage the cancer has reached by the time it is properly identified. While not every case of vulvar inflammation is cancer, persistent or changing vulvar symptoms warrant a biopsy rather than repeated empirical treatment.
Immunotherapy and Emerging Treatments
For patients with recurrent or advanced vulvar cancer that has progressed through standard treatment, immunotherapy has become an option, though a modest one so far. Pembrolizumab, a checkpoint inhibitor, produced response rates of 6% to about 11% in two clinical trials, with median overall survival of a few months to about half a year. Nivolumab showed a 20% response rate. Combination strategies, such as pembrolizumab with vorinostat, achieved somewhat better results, with median overall survival reaching about 17.5 months. Toripalimab showed a response rate of about a third of patients.28PubMed. Efficacy and safety of targeted therapy and immunotherapy in advanced vulvar squamous cell carcinoma: A scoping review These numbers are for heavily pretreated patients with limited options, so even modest activity is clinically meaningful, but immunotherapy is not yet a game-changer for most vulvar cancer patients the way it has been for some other cancers.
The pipeline holds some promise. Researchers have found that vulvar squamous cell carcinomas express several proteins that can be targeted by antibody-drug conjugates, a newer class of cancer drugs that deliver chemotherapy directly to tumor cells. Early exploratory data suggest that both HPV-associated and HPV-independent vulvar cancers may be candidates for this approach.29Gynecologic Oncology. Exploring novel therapeutic targets in vulvar squamous cell carcinoma Clinical trials testing antibody-drug conjugates and other targeted therapies in vulvar cancer are being advocated for and designed.30PubMed. Advances in Vulvar Cancer Biology and Management For patients with advanced or recurrent stage III disease, asking about clinical trial eligibility is always worthwhile, because the treatment landscape for this cancer is actively evolving in ways it was not even five years ago.